Almost 60% of HIV Patients Found to be Tenofovir-Resistent
HealthDay News — HIV resistance to the antiretroviral drug tenofovir (Viread) is common, according to a study published online January 28 in The Lancet Infectious Diseases.
Investigators looked at 1926 HIV patients from 36 countries with treatment failure between 1998 and 2015.
Tenofovir-resistant HIV strains were found in 57% of patients in sub-Sahara Africa. The researchers also found that, of 700 individuals with tenofovir resistance, 83% had cytosine analogue resistance (M184V/I mutation), 78% had major non-nucleotide reverse-transcriptase inhibitor resistance, and 65% had both.
"Tenofovir is a critical part of our armamentarium against HIV, so it is extremely concerning to see such a high level of resistance to this drug," study author Ravindra Gupta, MD, PhD, from the department of infection and immunity at University College London, said in a university news release. "It is very potent drug with few side effects, and there aren't any good alternatives that can be deployed using a public health approach. Tenofovir is used not only to treat HIV but also to prevent it in high-risk groups, so we urgently need to do more to combat the problem of emerging resistance."
Several authors disclosed financial ties to the pharmaceutical industry.